Catalog No.: PC-23063Not For Human Use, Lab Use Only.
Sontigidomide (BTX-1188) is a first-in-class dual degrader of GSPT1 and IKZF1/3 with DC50 of 0.2 nM, 1 nM and 1 nM for GSPT1, IKZF1 and IKZF3 respectively, in DOHH-2 (lymphoma) cells.
Sontigidomide (BTX-1188) is a first-in-class dual degrader of GSPT1 and IKZF1/3 with DC50 of 0.2 nM, 1 nM and 1 nM for GSPT1, IKZF1 and IKZF3 respectively, in DOHH-2 (lymphoma) cells.
BTX-1188 potently inhibits AML and solid tumor cell proliferation.
Sontigidomide (BTX-1188) potently inhibits aCD3-stimulated and LPS-induced cytokine induction in human PBMCs.
BTX-1188 is cytotoxic in various cancer cell lines such as MYC-dependent and non-MYC dependent lines (IC50 range: 0.5-20 nM) and primary human AML patient samples (IC50 range: 0.4-1.5 nM), including relapsed/refractory-, cytarabine and Venetoclax-resistant samples.
BTX-1188 (25 mg/kg, i.p. QD) is highly efficacious in NCI H1155 (NSCLC) xenograft model in BALB/c nude mice.
